<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210202050223N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-04-24</date_registration>
      <primary_sponsor>Shahroud University of Medical Sciences</primary_sponsor>
      <public_title>the effect of circadian rhythm disturbance on reward circuit and psychological functions</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the circadian rhythm disturbance impacts on the  human reward system, impulsivity and cognitive performance</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-05-13</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>34</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/54084</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: To equal the sample size in the two groups, the block method with a volume of 4 is used. For this purpose, 6 to four blocks will be created as follows
1- AABB
2- ABAB
3- ABBA
4- BBAA
5- BABA
6- BAAB
Where A is for the intervention group and B is for the control group The random assignment will be done in such a way that a random number will be created in Excel from 0 to 9 first. Depending on which block the random number belongs to, the sequence of that block is used to assign the subjects to the control and intervention group.For example, if the random number generated is 6, the first person will be assigned to group B, the second person to group A, the third person to group A, and the fourth person to group B. To reach the calculated sample size, the random number creation will be repeated 9 times Because each time the task is assigned, four diseases are identified. It should be noted that if the random number generated is 7, 8, 9 and 0, it will be ignored.
Envelopes in which the specified group is placed are used to conceal the allocation. Envelopes are numbered. After filling in the basic information of the people, an envelope is opened according to the word order of the people and the person is assigned to the desired group. To do this, 34 envelopes will be ready and individuals will be assigned to two groups.
The methodology consultant determines the allocation sequence. The registration of participants and their entry according to the entry and exit criteria and obtaining informed consent is the responsibility of a trained psychologist. Then, if they are eligible, it assigns them to groups based on closed envelopes, Blinding description: n this study, participants and analysts will not be aware of the results of the study. Also, in all outcome assessments conducted by questionnaires or interviews by a psychologist colleague, the research colleagues are unaware of how the participants are placed in the groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>circadian rhythm disorder (shift work type).</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The intervention for participants lasts for 9 days, the first 3 days are related to getting used to the conditions of the study environment.from the fourth day, the circadian rhythm disturbance protocol will be applied In the first three days of the study, participants eat breakfast at seven in the morning, lunch at noon and dinner at seven in the evening. From the fourth day, the intervention is as follows: breakfast at seven in the morning, lunch at seven in the afternoon and dinner at twelve at night.Sleep patterns in this group are also planned in such a way that the participants of the intervention group are awake during the night with 450 lux light in the room and are allowed to sleep at eleven o'clock in the morning every day until seven o'clock in the evening with 90 lux light. And research assistants oversee the accurate implementation of this model. Intervention 2: Control group: Participants in the control group are also present on the experimental site for 9 days,The meal times in the control group in all 9 days of presence in the experimental site are as follows: they eat breakfast at seven in the morning, lunch at noon and dinner at seven in the evening, and the patterns of sleeping and waking up are as follows: During the night, between eleven o'clock at night and seven o'clock in the morning, with 0 lux light, they can have a complete and normal night's sleep.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All personal data of the participants will share without name and personal information (unidentified)

When:
the access period start 6 months after results publication

To whom:
researcher who are working in academic and scientific institutions

Conditions:
the use of all data or documents for researcher for using in their research with reference to the source is allowed

Where to obtain:
To researcher of this study,Mohammad Niroumand Sarvandani refer to email address: m.niroumand@shmu.ac.ir

How to obtain:
by sending an email to m.niroumand@shmu.ac.ir.  all the demanded files will be provided to the applicant within 10 working days

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Niroumand Sarvandani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.108,Saman dormitory,Semnan,Shahroud,Iran</address>
        <city>Shahroud</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3614773955</zip>
        <telephone>+98 34 3245 4926</telephone>
        <email>m.niroumand@shmu.ac.ir</email>
        <affiliation>Shahroud University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Niroumand Sarvandani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.108,Saman dormitory,Semnan,Shahroud,Iran</address>
        <city>Shahroud</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3614773955</zip>
        <telephone>+98 34 3245 4926</telephone>
        <email>m.niroumand@shmu.ac.ir</email>
        <affiliation>Shahroud University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Male gender
right handed
Age range between 18 and 25 years
Regular rhythm of sleep and wakefulness in the past month (8 to 10) hours of sleep a night</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>25 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria>Having a history of psychiatric disorder
Having a history of substance abuse
Use of psychiatric drugs
Having a general medical disorder that endangers participants health during the test
Having a history of brain trauma
Having a metal body in the body, including platinum, fragments or iron particles
Having an irregular rhythm of sleeping and waking in the last month (8 to 10) hours of sleep at night (night shift work)
Having body mass index higher than 30</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G47.26</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Circadian rhythm sleep disorder, shift work type</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Lifestyle</i_code>
      <i_code>Lifestyle</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The intervention for participants lasts for 9 days, the first 3 days are related to getting used to the conditions of the study environment.from the fourth day, the circadian rhythm disturbance protocol will be applied In the first three days of the study, participants eat breakfast at seven in the morning, lunch at noon and dinner at seven in the evening. From the fourth day, the intervention is as follows: breakfast at seven in the morning, lunch at seven in the afternoon and dinner at twelve at night.Sleep patterns in this group are also planned in such a way that the participants of the intervention group are awake during the night with 450 lux light in the room and are allowed to sleep at eleven o'clock in the morning every day until seven o'clock in the evening with 90 lux light. And research assistants oversee the accurate implementation of this model.</i_keyword>
      <i_keyword>Control group: Participants in the control group are also present on the experimental site for 9 days,The meal times in the control group in all 9 days of presence in the experimental site are as follows: they eat breakfast at seven in the morning, lunch at noon and dinner at seven in the evening, and the patterns of sleeping and waking up are as follows: During the night, between eleven o'clock at night and seven o'clock in the morning, with 0 lux light, they can have a complete and normal night's sleep.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Impulsivity score in Bart's Impulsivity Questionnaire. Timepoint: Beginning of the intervention (before the start of the intervention) and end of the intervention (immediately after the end of the intervention). Method of measurement: Bart's Impulsivity Questionnaire.</prim_outcome>
      <prim_outcome>Assessment of Cognitive functions. Timepoint: Beginning of the intervention (before the start of the intervention) and end of the intervention (immediately after the end of the intervention). Method of measurement: Brief Cognitive Rating Scale.</prim_outcome>
      <prim_outcome>Assessment of presence or absence of  mood rhythmicity. Timepoint: Four hours before the intervention and four hours after the intervention. Method of measurement: Mood Rhythm Instrument (MRhI).</prim_outcome>
      <prim_outcome>Evaluation of the performance of the reward system (mesocortico limbic circuit). Timepoint: Three hours before the intervention and three hours after the intervention. Method of measurement: Functional magnetic resonance imaging.</prim_outcome>
      <prim_outcome>Performance in high-risk decision test (due to reaction time). Timepoint: Three hours before the intervention and three hours after the intervention. Method of measurement: Functional magnetic resonance imaging (GO/NO GO task).</prim_outcome>
      <prim_outcome>Vulnerability score for substance use and addictive behaviors test. Timepoint: Two hours before the intervention and two hours after the intervention. Method of measurement: Vulnerability to substance use and addictive behaviors test.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Impulsivity score in Bart's Impulsivity Questionnaire. Timepoint: Beginning of the intervention (before the start of the intervention) and end of the intervention (immediately after the end of the intervention). Method of measurement: Bart's Impulsivity Questionnaire.</sec_outcome>
      <sec_outcome>Assessment of Cognitive functions. Timepoint: Beginning of the intervention (before the start of the intervention) and end of the intervention (immediately after the end of the intervention). Method of measurement: Brief Cognitive Rating Scale.</sec_outcome>
      <sec_outcome>Assessment of presence or absence of mood rhythmicity. Timepoint: Four hours before the intervention and four hours after the intervention. Method of measurement: Mood Rhythm Instrument (MRhI).</sec_outcome>
      <sec_outcome>Evaluation of the performance of the reward system (mesocorticolimbic circuit). Timepoint: Three hours before the intervention and three hours after the intervention. Method of measurement: Functional magnetic resonance imaging.</sec_outcome>
      <sec_outcome>Performance in high-risk decision test (due to reaction time). Timepoint: Three hours before the intervention and three hours after the intervention. Method of measurement: Functional magnetic resonance imaging (GO/NO GO task).</sec_outcome>
      <sec_outcome>Vulnerability score for substance use and addictive behaviors test. Timepoint: Two hours before the intervention and two hours after the intervention. Method of measurement: Vulnerability to substance use and addictive behaviors test.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahroud University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-02-07</approval_date>
        <contact_name>Ethics committee of Shahroud university of medical science</contact_name>
        <contact_address>Shahroud University of Medical Sciences and Health Services, Hafte Tir Square, Shahroud, Iran shahroud Semnan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
